CT analysis and differentiation of clear cell renal cell carcinoma and renal oncocytoma
10.3969/j.issn.1002-1671.2019.10.018
- VernacularTitle:肾透明细胞癌及肾嗜酸细胞腺瘤的多层螺旋CT分析与鉴别
- Author:
Yisi DAI
1
;
Xiaoping YIN
;
Qian WANG
;
Yang LIU
;
Xuxin YAN
Author Information
1. 河北大学
- Keywords:
computed tomography;
clear cell renal cell carcinoma;
renal oncocytoma
- From:
Journal of Practical Radiology
2019;35(10):1627-1631
- CountryChina
- Language:Chinese
-
Abstract:
Objective To probe the difference of MSCT features between clear cell renal cell carcinoma (ccRCC)and renal oncocytoma (RO),to improve the diagnostic accuracy.Methods 31 cases of ccRCC and 16 cases of RO which were confirmed by pathology were analyzed retrospectively,and the difference in some CT features including the morphology and CT value of plain scanning and three phases of enhancement scanning were analyzed.Results The diameter of the tumor of the ccRCC group was (5.04 ± 1.9 1 4)cm,meanwhile that of the RO group was (3.5 9±2.1 6)cm,exhibiting statistically significant difference in the diameter which was bigger in ccRCC group than that in RO group (P=0.023).There were 90.32% (28/31)of cases with cystic necrosis in the ccRCC group and 18.75%(3/16)in the RO group,which was statistically significant that the patients with cystic deterioration in the ccRCC group were more than those in the RO group (P<0.001).35.48% (11/31)of cases with peritumoral or intratumoral neovascularization in the ccRCC group and no cases in the RO group were found,and there was a statistically significant difference (P=0.009).The enhancement degree in the ccRCC group was greater than that in the RO group in cortical phase and excretory phase,but lower in parenchy phase.However, there was no significant difference in the enhancement degree and the enhancement index in three phases of enhancement scanning (P>0.05). Conclusion MSCT can demonstrate the renal tumor with or without cystic necrosis and neovascularization around or inside the tumor,which is helpful to differentiate ccRCC from RO.